Anti-PCV-2 polyclonal antibody

This study aimed to evaluate the use of a sodium alginate matrix-pelletized formulation of Duddingtonia flagrans for biological control of gastrointestinal nematodiasis in feedlot goats in the semiarid region of Northeastern Brazil. We used 20 Saanen female goats (age, 4 months; average weight, 12 kg) that did not receive anthelmintic treatment and had counting of eggs per gram of faeces (EPGs) >= 500. The animals were divided into two groups: in group 1 (D. flagrans group), each animal received 3 g of pellets (0.6 g of D. flagrans mycelium) per 10 kg of body weight, twice a week, over 4 months; and in group 2 (control group), each animal received 3 g of pellets without fungus per 10 kg of body weight, twice a week, over 4 months. Each group was maintained in a separate 15-m(2) stall. Larval cultures and measurements of weight, EPG, and packed cell volume (PCV) were performed every 15 days. We observed low EPG levels in the D. flagrans group throughout the experimental period, with a significant difference (p < 0.05) on day 30 and from day 60, having, at the end of the experiment, average OPG values of only 150, reduction of 92.3% when compared to control group. Haemonchus sp. was the most prevalent helminth in all larval cultures. The D. flagrans group showed a mean weight gain of 8.8 kg at the end of the experiment (p < 0.05), while the control group showed a mean weight gain of 4.8 kg. The best PCV results (p < 0.05) were also observed in the D. flagrans group from day 30. Thus, the use of D. flagrans pellets in a sodium alginate matrix was effective in controlling gastrointestinal nematodiasis of feedlot goats in the semiarid region of Northeastern Brazil.

Background: Low vaccination coverage as well as incomplete and delayed vaccinations pose a risk for the individual and population protection from vaccine-preventable diseases. Aim: To describe vaccination patterns for nationally recommended basic and supplementary vaccinations in Swiss preschool children. Methods: We performed a descriptive study based on administrative claims data from a large Swiss health insurer (Helsana), in cohorts of children born between January 2010 and December 2016. We assessed coverage rates of nationally recommended basic vaccinations (i.e., diphtheria, tetanus, acellular pertussis Haemophilus influenzae type b [Hib], poliomyelitis [IPA, measles, mumps, and rubella [MMR]) and supplementary vaccinations (i.e., pneumococcal conjugate vaccine [PCV] and meningococcal group C conjugate vaccine [MCV]) for each birth cohort at the age of 13, 25, and 37 months. Additionally, we analysed timeliness of vaccinations using inverse Kaplan-Meier curves. Results were extrapolated to the Swiss population. Results: The study population comprised 563,216 children. We observed continuously increasing coverage rates for all vaccinations until the 2015 birth cohort. Overall, up-to-date status for the first dose of studied vaccinations at 37 months was as follows: DTaP: 95.4%; Hib: 94.9%; IPV: 95.5%; MMR: 86.8%; PCV: 83.2%; and MCV: 66.7%. On average, however, only seven out of ten children had an up-to-date status for completed basic vaccinations; even less (six out of ten) were up-to-date for recommended supplementary vaccinations at 37 months of age. Moreover, 4% of all analysed children received none of the recommended vaccinations and there were substantial regional differences. Delays in vaccine administration were common. The most frequently postponed basic vaccination was MMR; 22.6% of children vaccinated with the first dose experienced delays relative to age-appropriate standards. Conclusion: To avoid future outbreaks and transmission of vaccine-preventable diseases, vaccination coverage in Switzerland must be further improved. In addition, more emphasis should be placed on timely vaccination. (C) 2019 Elsevier Ltd. All rights reserved.